Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent covering LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, thereby reinforcing Lantern Pharma's strategy for global commercialization of LP-284.
Developed using Lantern’s innovative RADR(R) AI platform, LP-284 is currently undergoing Phase 1 clinical trials. The drug has also been awarded Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL), highlighting its potential to address unmet medical needs in these areas. With a target market estimated at $4 billion globally, LP-284 represents a significant opportunity for Lantern Pharma. The drug's rapid development timeline and cost efficiency, underscored by the company's ability to advance programs from initial AI insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program, further enhance its appeal for strategic partnerships.
For more details on this development, visit https://ibn.fm/Rx6Jq. Additional information about Lantern Pharma and its pipeline can be found at https://ibn.fm/LTRN.
